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ABSTRACT
The efficacy of topical corticosteroids as ocular
anti-inflammatory agents following cataract
surgery is well-documented. They also help to
prevent a number of complications associated
with post-operative ocular inflammation,
including corneal edema and cystoid macular
edema. However, topical corticosteroids
are associated with side effects, such as
increased intraocular pressure (IOP). Indeed,
corticosteroid-induced ocular hypertension
and the potential for steroid-induced glaucoma
remain the leading drawbacks of topical
corticosteroid therapy. Some individuals are
known to experience a high degree of IOP
elevation with low doses or short durations of
treatment with topical corticosteroids. Careful
monitoring of IOP in such individuals is essential.
Few randomized, controlled studies are available
on the comparative safety and efficacy of
common topical corticosteroids in the treatment
of post-operative ocular inflammation.
Furthermore, the lack of consistent reporting
criteria for clinically significant IOP increases
across clinical studies makes meaningful
comparisons among corticosteroids difficult.
This review aims to examine data from
available published studies, including studies
in steroid responders, to determine whether
topical corticosteroids are the same in terms of
their effect on IOP. Early generation
corticosteroids, such as dexamethasone and
prednisolone, are more likely to result in
clinically significant increases in IOP. Newer
corticosteroids, such as rimexolone and the
retro-metabolically designed corticosteroid,
loteprednol etabonate, offer similar
anti-inflammatory efficacy to older
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corticosteroids with less effect on IOP. However,
randomized controlled trials of newer
corticosteroids are needed. The proportion of
patients exhibiting an increase of C10 mmHg
IOP in clinical studies has emerged as the
most clinically relevant parameter for
ophthalmologists to consider when deciding
on which topical corticosteroid to use.




Surgical trauma to the eye initiates an
inflammatory reaction. This reaction includes
the release of prostaglandins and the
recruitment of neutrophils and macrophages
to the site of trauma [1]. Although usually self-
limited, post-operative ocular inflammation
after cataract surgery can be associated with
complications, includingcorneal edema, spikes in
intraocular pressure (IOP), cystoid macular edema
(CME), and posterior capsule opacification [1]. As
most patients expect 20/20 vision after cataract
surgery without any complications, the use of
prophylactic anti-inflammatory agents is a
standard practice.
Topical corticosteroids are routinely used in
the treatment of post-operative inflammation
following cataract surgery [2–5] as well as
after most other ocular surgical procedures
[6–9]. Corticosteroids reduce intraocular
inflammation, which is most often measured
by anterior segment cell and flare reaction. They
also alleviate associated symptoms, such as
photophobia, swelling, pain, and tenderness.
At a histological level, corticosteroids suppress
cellular infiltration, capillary dilation, the
proliferation of fibroblasts, collagen
deposition, and eventually scar formation [10].
At a cellular level, they stabilize intracellular
and extracellular membranes, and increase the
synthesis of anti-inflammatory lipocortins.
Lipocortins, in turn, block phospholipase A2,
the enzyme responsible for conversion of
phospholipids to arachidonic acid, the first
step in the inflammatory cascade (Fig. 1)
[11–13]. Corticosteroids mediate their anti-
inflammatory effects primarily through the
glucocorticoid receptor by direct and indirect
actions at the genomic level [14]. Recent work
suggests that the activated corticosteroid–
receptor complex also elicits nongenomic
effects, particularly in the inhibition of
vasodilation, vascular permeability, and
migration of leukocytes [14].
Although topical ocular corticosteroids are a
vital component of the treatment of post-
operative inflammation, their prolonged use
can produce side effects, such as increased
IOP, cataract formation (in phakic
individuals), and lowered resistance to
infection [1, 11, 15–17]. Research shows that
elevated IOP, if left untreated, may lead to
progressive optic nerve damage and
glaucomatous visual field defects, ultimately
culminating in corticosteroid-induced
glaucoma [18]. The mechanism whereby
topical corticosteroids increase IOP is not fully
Fig. 1 The inﬂammatory pathway. PG prostaglandin
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understood. The glucocorticoid receptor is
involved in multiple, diverse signaling
pathways, and it is thought that steroid-
induced IOP elevation, particularly that
observed with long-term use or high doses of
corticosteroids, is the result of upregulation or
repression of one or more genes unrelated to the
indication being treated [19]. Most studies
implicate trabecular meshwork (TM) cells and
myocilin gene expression in the mechanism of
corticosteroid-induced IOP elevation.
Corticosteroids appear to decrease the outflow
of aqueous humor by inhibiting the
degradation and/or enhancing the deposition
of extracellular matrix material within the TM
and/or cross-linking of actin fibers between TM
cells [20]. The TM accounts for the majority of
drainage from the eye; it appears to be this
resistance to aqueous outflow (caused by
changes to the TM and its extracellular matrix)
that eventually leads to an increase in IOP.
Indeed, early ultrastructural studies revealed an
increase in extracellular ground substance of
the corneo-scleral trabeculum in steroid-
induced glaucoma [21]. Clark and Wordinger
[22] suggested that structural changes in the
TM, in turn, result in corticosteroid-induced
ocular hypertension, which can progress to
secondary iatrogenic open-angle glaucoma.
Myocilin, initially referred to as TM-inducible
glucocorticoid response or TIGR gene product,
is a 55-kDa protein induced after exposure of
TM cells to dexamethasone for 2–3 weeks,
which is also closely associated with decreased
aqueous humor outflow and steroid-induced
IOP increase [23, 24]. Different mutations
within the myocilin gene lead to a variety of
glaucoma phenotypes in both juvenile and
adult-onset primary open-angle glaucoma,
providing further evidence for its role in
steroid-induced IOP. Fan et al. [25] compared
the effects of triamcinolone acetonide and
dexamethasone on the differential gene
expression profile of human TM cells and
found that both steroids induced or repressed
the same genes, suggesting a common
mechanism for steroid-induced ocular
hypertension at the cellular level. It follows
that any differences among topical
corticosteroids in IOP effects are influenced by
differences in ocular tissue penetration and
half-life. Figure 2 [26] explores the proposed
mechanism of action of corticosteroid-induced
IOP elevation; however, further research into
the details surrounding this mechanism of
action is certainly warranted.
The objective of this article was to review
differences in IOP effects among common
topical ophthalmic corticosteroids used to
treat inflammation following cataract surgery.
METHODS
Publications were identified through a search of
MEDLINE/PubMed from 1946 to 2013
using any of the terms ‘‘anti-inflammatory
agents,’’ ‘‘androstadienes,’’ ‘‘pregnadienes,’’
‘‘glucocorticoid drug,’’ ‘‘corticosteroids,’’ and
‘‘glucocorticoids,’’ then limited to those results
including the terms ‘‘cataract extraction’’ or
‘‘cataract surgery’’ and then ‘‘IOP’’ or
‘‘intraocular pressure.’’ Results were limited to
only those studies conducted in humans and
reported in English. In addition, a few studies
specifically examining corticosteroid-induced
changes in IOP in those individuals with
previously documented steroid response were
identified to provide a perspective on the IOP
effects of steroids in responders. Overall,
randomized, controlled clinical studies using
prednisolone, dexamethasone, fluorometholone,
loteprednol etabonate, rimexolone, and
difluprednate formed the vast majority of
these results. We focused on data from studies
Ophthalmol Ther (2013) 2:55–72 57
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Fig. 2 Proposed mechanism of action of corticosteroid-induced increase in intraocular pressure
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on loteprednol etabonate, rimexolone, and
difluprednate because these three drugs have
been formally approved by the United States
Food and Drug Administration (FDA) and in
various European and Asian countries for
the specific indication of post-operative
inflammation. We also reviewed the older
corticosteroids prednisolone, dexamethasone,
and fluorometholone because these are
still commonly used. Although the primary
focus was on topical corticosteroids used
in the treatment of post-operative ocular
inflammation after cataract surgery, other







As indicated previously, while the efficacy of
topical ocular corticosteroids in the treatment
of ocular inflammation has been shown, they
also have the potential of increasing IOP [1, 11,
13, 15, 16, 19, 27–31]. However, to date,
meaningful comparisons of the potential for
corticosteroid-induced increase in IOP with
different corticosteroids have been hampered
by a lack of a standard format for testing and
reporting clinically significant IOP elevations
[18]. In the mid-1960s, Becker used absolute IOP
as the criterion, with 20 mmHg being the lower
limit of a clinically significant response, while
Armaly [32, 33] classified the IOP response as a
relative difference (treated vs. untreated eye),
with a difference of 6 mmHg being the lower
limit of a clinically significant response. In
1984, Stewart et al. [34] conducted a study
comparing the ocular pressure effects of
fluorometholone acetate and dexamethasone
sodium phosphate in steroid responders, and
proposed that an increase in IOP of C10 mmHg
over baseline should be considered clinically
significant. This value was readily accepted by
the ophthalmic community; it has since been
adopted by the United States FDA, and many
subsequent studies have associated an increase
in IOP of C10 mmHg over baseline with clinical
significance [2, 4, 5, 35–40]. Nonetheless, many
relatively recent studies still fail to report this
outcome. Below, we review published studies
on topical ophthalmic corticosteroids used in
post-operative inflammation, noting any
reports of IOP elevations of C10 mmHg where
available.
Older Corticosteroids
Because early generation corticosteroids,
including dexamethasone, prednisolone, and
fluorometholone, were introduced prior to
current regulatory requirements, pivotal
placebo-controlled clinical trials are lacking.
However, a few recent comparative studies
were found in the literature and provide an
insight to their IOP effects.
Saari et al. [41] compared the anti-
inflammatory effects of 0.7% dexamethasone-
cyclodextrin aqueous solution instilled once
daily and 0.1% dexamethasone sodium
phosphate instilled three-times daily in 20
patients undergoing cataract surgery. Patients
were randomized to receive study treatment
post-operatively and were assessed on post-
operative days 1, 3, 7, and 21. Laser flare cell
meter measurements showed that on post-
operative day 21 patients treated with 0.7%
dexamethasone-cyclodextrin demonstrated
lower mean post-operative photon count and
mean cell count (P B 0.032) than those treated
with dexamethasone sodium phosphate. No
significant differences in the mean [standard
Ophthalmol Ther (2013) 2:55–72 59
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deviation (SD)] IOP were observed between
treatment groups [14.0 (3.1) vs. 14.3 (2.1)
mmHg at final visit] [41]. However, IOP
elevations of C10 mmHg over baseline were
not reported. Laurell and Zetterstrom [30]
compared the effects of treatment with
dexamethasone, diclofenac, or placebo in 180
patients after phacoemulsification and
intraocular lens (IOL) implantation.
Inflammation was measured by laser flare
photometry pre-operatively and at 1, 3, and
8 days, 2 and 4 weeks, 2 and 6 months, and 1, 2,
and 4 years post-operatively. Dexamethasone
and diclofenac were more efficacious than
placebo and were equally efficacious in the
reduction of post-operative inflammation. At
post-operative day 8 and 1 month, a
significantly higher mean IOP was observed in
the dexamethasone group when compared with
the placebo group (16 vs. 13 mmHg at day 8,
and 15 vs. 14 mmHg at 1 month, respectively;
P\0.05 for both). The authors reported that no
patient exhibited an increase in IOP of
C10 mmHg [30].
Lorenz et al. [42] studied the effects of
prednisolone acetate 0.5% on intraocular
inflammation after phacoemulsification.
Prednisolone acetate 0.5% or placebo was
instilled in 62 patients four-times daily until
day 2 post-operatively. All patients were then
treated with open-label prednisolone acetate
0.5% administered four-times daily until
day 14. A significant difference between
prednisolone acetate and placebo was observed
on post-operative day 3 in protein flare (20.8 vs.
32.6 photon counts/ms, respectively;
P = 0.0055) while flare measures were
comparable at day 14 (13.0 and 11.4 photon
counts/ms, respectively). Increased IOP (degree
of increase not reported) was observed in three
patients (4.8%), although mean IOP was
considered normal (\21 mmHg) in both
groups at the end of the treatment period [42].
Smerdon et al. [43] compared the efficacy and
safety of prednisolone 0.5% with placebo
(vehicle) in the control of inflammation
following cataract extraction in 120 patients.
Treatment with tolmetin 2% was included in
the study as the third treatment arm.
Treatments were administered four-times daily
for 6 weeks. Resolution of post-operative
inflammation was reported for a significantly
higher proportion of patients in the
prednisolone group compared to the placebo
group (94% vs. 46%, respectively; P\0.001).
Seven patients (24%) in the prednisolone group
when compared with three patients (9%) in the
placebo group had IOP elevated to [22 mmHg
during the trial. However, the authors did not
report whether any IOP elevations were
C10 mmHg above baseline.
Our literature search failed to identify
randomized, placebo-controlled studies of
fluorometholone in post-cataract surgery.
However, Trinavarat et al. [44] compared the
efficacy and adverse effects of prednisolone
acetate 0.5%, ketorolac tromethamine 0.5%
and fluorometholone acetate 0.1% in patients
with post-operative inflammation following
cataract surgery. A total of 120 eyes were
enrolled in this prospective, investigator-
masked, randomized controlled trial with each
drug administered four-times daily for 4 weeks.
All treatments were effective in the primary
outcome measure—reducing inflammation
after phacoemulsification. Mean IOP was
higher in the prednisolone group when
compared with the ketorolac group on day 21
(14.6 vs. 12.2 mmHg, respectively; P = 0.016)
but did not differ from the fluorometholone
group (13.8 mmHg). One eye in the
prednisolone group had an IOP of 32 mmHg
on day 21 and was terminated from the study.
Vetrugno et al. [45] compared the efficacy and
60 Ophthalmol Ther (2013) 2:55–72
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tolerability of fluorometholone 0.1% acetate
and fluorometholone 0.2% in two groups of
30 patients who had undergone myopic
photorefractive keratectomy. Patients instilled
treatments four-times daily for 1 month,
followed by treatment application at
decreasing frequency every 3 weeks. No
significant differences were observed in visual
acuity, haze, and mean IOP between the two
groups, although mean IOP increased relative to
baseline in both groups. Three patients in the
fluorometholone 0.2% group and two patients
in the fluorometholone acetate 0.1% group had
increased IOP at 15 and 30 days
(fluorometholone 0.2% group: 28, 31,
26 mmHg; fluorometholone 0.1% acetate
group: 27, 26 mmHg). The authors did not
report whether any of these elevations were
C10 mmHg over baseline, but indicated that
IOP-lowering medication was administered.
While these studies demonstrate the efficacy
of older corticosteroids for post-operative
inflammation, safety findings suggest potential
IOP effects with all three corticosteroids. The
lack of consistent IOP reporting precludes
more meaningful comparisons across these
studies.
Newer Corticosteroids
Rimexolone, difluprednate, and loteprednol
etabonate are relatively recent ophthalmic
corticosteroids introduced during today’s more
comprehensive regulatory environment. Hence,
pivotal placebo-controlled clinical trials, as well
as comparative trials for these steroids are
available in the literature. Table 1 [2–5, 40,
46–48] summarizes comparative rates of
resolution of inflammation and clinically
significant increases in IOP observed with each
of these three newer corticosteroids in placebo-
controlled trials.
Rimexolone is a highly lipophilic
glucocorticoid that lacks a hydroxyl
substituent at the 21-position of the core
corticosteroid structure [49, 50]. Foster et al.
[37] suggested that the lipophilicity of
rimexolone results in a balance between
efficacy and safety. Specifically, rimexolone is
thought to achieve ocular tissue levels sufficient
to treat inflammation, while its limited ocular
penetration and biological half-life minimize
any IOP effects [37]. Bron et al. [3] examined the
efficacy and safety of a 2-week regimen of
rimexolone 1% as compared to placebo in
reducing post-operative inflammation in 182
post-cataract patients. The proportion of
patients showing resolution of anterior
chamber inflammation (ACI) was 50% and
21.1% for the rimexolone and placebo groups,
respectively (P = 0.0003), on post-operative
day 15. Rimexolone-treated patients had
significantly less bulbar conjunctival erythema,
corneal edema, anterior vitreous reaction, and
ocular discomfort (P\0.05). No perceptible
changes in IOP were reported for either group,
but the authors noted that the study was not
designed to show differences in IOP response.
Assil et al. [46] also compared rimexolone to
placebo for post-operative inflammation in 196
post-cataract patients. ACI was completely
resolved in 59.7% and 19.6% of patients in the
rimexolone and placebo groups, respectively,
on day 15 post-operatively. There was no
between-group difference in mean (SD) IOP on
day 15 [15.7 (4.7) and 14.9 (3.3) mmHg in the
rimexolone and placebo groups, respectively;
P = 0.32]. However, two patients in each group
exhibited an increase in IOP of C10 mmHg over
baseline.
Yaylali et al. [51] compared the efficacy and
safety of rimexolone 1% to prednisolone acetate
1% in 48 post-cataract patients. Treatments
were administered four-times daily for 15 days
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post-operatively, and patients were examined
on post-operative days 1, 3, 7, and 15. Anterior
chamber cell and flare, and conjunctival
hyperemia were the main efficacy parameters;
IOP was assessed as a safety parameter. Across all
efficacy parameters, rimexolone was equivalent
to prednisolone acetate 1%, with the exception
of mean (SD) number of anterior chamber cells
at day 3 [0.55 (0.5) vs. 0.19 (0.40), respectively;
P = 0.01]. Post-operative IOP values were also
similar between treatment groups, with the
exception of day 3, on which the mean (SD)
IOP was found to be higher in the prednisolone
group [11.9 (1.9) vs. 10.9 (1.3) mmHg;
P = 0.038]. IOP increases C10 mmHg from
baseline were not reported. Kavuncu et al. [52]
also compared the efficacy and safety of
rimexolone 1% with that of prednisolone
acetate 1.0%. Patients (n = 80) undergoing
cataract extraction with IOL implantation
were randomized to receive either
prednisolone acetate or rimexolone every 4 h
for 18 days. There were no differences between
treatments in anterior chamber cell count or
flare. Treatment with rimexolone was associated
with higher conjunctival hyperemia on days 1
and 3 (P\0.05), while treatment with
prednisolone acetate was associated with
higher corneal edema on day 8 (P\0.05).
There were no between-treatment differences
in the mean IOP at any visits, with IOP ranging
from 11.1 to 14.0 and 10.5–14.7 mmHg in the
prednisolone acetate and rimexolone groups,
respectively.
Difluprednate, a derivative of prednisolone
that is difluorinated at the C6 and C9 positions
[4], is approved for treating post-operative
inflammation in the United States and some
countries in the European Union. Originally
developed for dermatologic applications, it was
also found to rapidly penetrate the corneal
epithelium [4]. Korenfeld et al. [4] compared
the efficacy and safety of difluprednate
ophthalmic emulsion 0.05% with that of
placebo (vehicle) in 438 patients with
inflammation after ocular surgery in two
studies. Difluprednate and placebo were
instilled twice daily in one study and four-
times daily in the other. Both difluprednate
regimens were effective in reducing pain and
inflammation post-operatively as compared to
placebo. The proportion of patients with
resolution of anterior chamber cells (grade 0
cells) on day 8 was 30%, 35%, and 9% in the
difluprednate group with the twice-daily dose
regimen, difluprednate group with the four-
times daily dose regimen, and the pooled
placebo group, respectively (P\0.0001 vs.
placebo for both difluprednate regimens).
However, 3% of patients in both difluprednate
groups exhibited an increase in IOP of
C10 mmHg from baseline to an IOP of
C21 mmHg as compared to 1% of patients in
the placebo group. Smith et al. [40] also
compared the efficacy and safety of
difluprednate ophthalmic emulsion 0.05%
with that of placebo (vehicle) in 121 patients
undergoing cataract surgery. In this study,
dosing was initiated 24 h before surgery and
consisted of twice-daily administration for
16 days, followed by a 14-day tapering period.
Resolution of ACI (anterior cells grade, 0; flare
grade, 0) on day 14 was higher among patients
in the difluprednate group than in the placebo
group (74.7% vs. 42.5%, P = 0.0006). Again,
three patients (3.7%) in the difluprednate group
had an increase in IOP of C10 mmHg from
baseline to an IOP of C21 mmHg as compared
with none of the patients in the placebo group.
The IOP-increasing potential of
difluprednate was further investigated by
Cable in a retrospective chart review [53].
Data from 100 consecutive, uncomplicated
phacoemulsification patients treated with
Ophthalmol Ther (2013) 2:55–72 63
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difluprednate ophthalmic emulsion 0.05%
twice daily post-operatively were analyzed.
Five percent of patients, all with a history of
open-angle glaucoma, responded with ocular
hypertension. The average increase in IOP
among responders was 17.8 mmHg,
considerably higher than the accepted value
for a clinically significant increase (C10 mmHg).
Moreover, 60% of IOP elevations were noted on
post-operative day 1 and a further 40% on post-
operative day 7. The authors concluded that
difluprednate administered twice daily could
cause significant and early elevations in IOP.
Loteprednol etabonate is approved for the
treatment of post-operative inflammation in
the United States and most countries in the
European Union. Loteprednol etabonate differs
from other ophthalmic corticosteroids in that it
has an ester rather than a ketone at the C-20
position of the core corticosteroid structure
[54]. Loteprednol etabonate was designed
through retro-metabolic drug design; a process
by which an inactive, non-toxic metabolite of a
reference compound, in this case prednisolone,
is chemically modified to a therapeutically
active compound [55, 56]. Clinically,
following ocular penetration and saturation of
the glucocorticoid receptor in ocular tissues,
unbound loteprednol etabonate undergoes
rapid de-esterification to its inactive
metabolite, D1 cortienic acid etabonate, or
PJ-91, resulting in a decreased impact on IOP
[39, 56–58]. The efficacy and safety of
loteprednol etabonate 0.5% suspension in
post-operative inflammation were
demonstrated in two placebo-controlled
studies (n = 227 and n = 203, respectively) [2,
5]. In both studies, patients were randomized to
either loteprednol etabonate 0.5% or vehicle
four-times daily for up to 14 days after cataract
surgery. In the first study, ACI was resolved in
64% and 29% of patients in the loteprednol
etabonate and vehicle groups, respectively;
while in the second study, ACI was resolved in
55% and 28% of patients, respectively
(P\0.001 for both studies) at post-operative
day 15. A post hoc analysis of pooled data from
both studies showed that pain was resolved in
84% and 56% of patients with baseline pain
scores of [0 for the loteprednol etabonate and
vehicle groups, respectively (P\0.05) [59]. In
both studies, there was an overall mean
decrease in IOP of 1–2 mmHg for the
loteprednol etabonate- and vehicle-treated
patients at all post-operative visits relative to
screening, with no significant differences
between the treatment groups in either study.
A clinically significant increase in IOP
(C10 mmHg) over baseline was observed in
three patients in the loteprednol etabonate
group in the first study and in one patient
receiving the vehicle in the second study.
Lane and Holland compared the efficacy and
safety of loteprednol etabonate 0.05% with that
of prednisolone acetate 1.0% (Pred Forte,
Allergan, Inc., Irvine, CA, USA), administered
four-times daily in 88 patients following routine
cataract surgery and found similar control of
inflammation after surgery [60]. At post-
operative days 1, 3, 7, and 21, mean IOP and
mean change in IOP were higher in patients
treated with prednisolone acetate than in those
treated with loteprednol etabonate, although
this did not reach statistical significance. One
patient in the prednisolone acetate treatment
group had a clinically significant increase in IOP
(C10 mmHg) over baseline.
Fong et al. and Rajpal et al. [47, 48] recently
examined the efficacy and safety of a gel
formulation of loteprednol etabonate as
compared to vehicle (both dosed four-times a
day) in reducing post-operative inflammation
and pain in post-cataract patients (n = 407 and
n = 406, respectively). The gel contains 0.5%
64 Ophthalmol Ther (2013) 2:55–72
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loteprednol etabonate in a non-settling
formulation intended to provide consistent
dose uniformity without the need to shake.
In both multicenter, randomized, masked
studies a greater proportion of loteprednol
etabonate-treated patients had complete
resolution of anterior chamber cells on Day 8
as compared to vehicle-treated patients (31.1%
vs. 13.9% and 30.5% vs. 16.3%, respectively;
P\0.001 for both). Similarly, a greater
proportion of loteprednol etabonate-treated
patients had grade 0 pain (75.7% vs. 45.8%
and 72.9% vs. 41.9%, respectively, P\0.001
for both). In both studies mean IOP was
consistently lower than baseline for both
treatment groups at follow-up visits. Two
patients in the loteprednol etabonate-
treatment group and one patient in the
vehicle group exhibited a clinically significant
increase from baseline in IOP (C10 mmHg)
across the two studies.
Low incidences of elevated IOP (C10 mmHg)
have also been observed in studies of
loteprednol etabonate suspension in the
treatment of giant papillary conjunctivitis,
seasonal allergic conjunctivitis, anterior
uveitis, and delayed tear clearance [35, 61–64]
or when loteprednol etabonate was used in
combination with tobramycin in the treatment
of blepharokeratoconjunctivitis [65–68].
Novack et al. [69] further examined the IOP
data from all patients enrolled in loteprednol
etabonate development trials in the United
States who received treatment for a period of
C28 days, and found that loteprednol etabonate
had minimal effect on IOP when used long
term. Of patients who received loteprednol
etabonate 0.5% or 0.2%, 1.7% (15/901)
exhibited IOP elevations of C10 mmHg over
baseline as compared with 6.7% (11/164) of
patients who were treated with prednisolone
acetate 1.0%. Among patients using loteprednol
etabonate 0.5%, only 2.1% (14/664)
demonstrated clinically significant increases in
IOP; this proportion was reduced to 0.8%
(3/387) when patients who continued to wear
contact lenses during treatment were
eliminated, suggesting that contact lenses
might potentially act as reservoirs for
corticosteroids [69].
Taken together, the above studies indicate
that the newer corticosteroids, i.e., rimexolone,
difluprednate, and loteprednol etabonate, offer
similar efficacies in terms of resolution of post-
operative inflammation. However, fewer
clinically significant increases in IOP appeared
to be associated with rimexolone and
loteprednol etabonate use when compared
with difluprednate use, likely due to ocular
pharmacokinetic differences among these
steroids. Further comparative studies are
needed, however. The most clinical data on
IOP effects was found for loteprednol etabonate
and suggested little effect on IOP associated
with loteprednol etabonate.
STUDIES IN STEROID RESPONDERS
Some patients have a documented history of
IOP increase in response to corticosteroid
treatment, in which a small dose of
corticosteroid or a short duration of treatment
may result in disproportionate increases in IOP.
First documented by Armaly and Becker in the
1960s [32, 70, 71], steroid responders generally
constitute 18–36% of the general population
[19]. Corticosteroid effects on IOP in such
patients are generally reversible; IOP will
usually return to pretreatment levels within
1–3 weeks if the treatment is discontinued [72].
Nevertheless, careful monitoring of IOP is
essential in such individuals. Longer axial
length has been identified as a risk factor for
steroid-induced IOP elevation [28]. In addition,
Ophthalmol Ther (2013) 2:55–72 65
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patients with primary open-angle glaucoma,
family history of glaucoma and status as a
glaucoma suspect are also at higher risk for
developing corticosteroid-induced ocular
hypertension [26, 67]. Most prospective studies
reviewed in the previous sections would have
excluded known steroid responders, as the risk
of developing a clinically significant change in
IOP would have been considered too high.
However, several published studies report on
the corticosteroid-induced IOP response in
known steroid responders. These studies are
extremely valuable in differentiating the
relative IOP effects among corticosteroids as
any differences will be more pronounced in this
study population.
Cantrill et al. [73] assessed the IOP-raising
potential of various topical corticosteroids in 10
known steroid responders. Steroid responders
were defined as those patients who developed
IOP of [31 mmHg after topical application of
dexamethasone 0.1% administered four-times
daily for 2–6 weeks. Patients were sequentially
tested with dexamethasone phosphate 0.005%,
medrysone 1%, tetrahydrotriamcinolone 0.25%,
hydrocortisone 0.5%, and prednisolone acetate
1%. Of the various corticosteroids studied,
dexamethasone 0.1% caused the maximum
increase in IOP, i.e., a mean [standard error (SE)]
increase of 22.0 (2.9) mmHg (Table 2) [73].
Akingbehin [74] compared the IOP effects of
fluorometholone 0.1% and dexamethasone 0.1%
administered four-times daily for 6 weeks in 15
patients with ocular hypertension or glaucoma by
using provocative testing. Thirteen patients (22
eyes) were first provoked with dexamethasone
and 6 months later, with fluorometholone. The
remaining two patients underwent simultaneous
bilateral testing with dexamethasone (right eye)
and fluorometholone (left eye). Drops were
discontinued if an increase in IOP of[15 mmHg
over baseline was observed. The mean increase in
IOP was 8.58 mmHg with dexamethasone
treatment as compared to 2.96 mmHg with
fluorometholone treatment (P\0.001). Post-
treatment IOP elevations of C10 mmHg were
observed in 45.8% and 4.2% of the
dexamethasone- and fluorometholone-treated
eyes, respectively. Stewart et al. [34] also
compared the IOP effects of fluorometholone
0.1% and dexamethasone 0.1% in patients who
had previously experienced an IOP increase of
C10 mmHg with dexamethasone. In this double-
masked, crossover study, 17 patients (17 eyes)
Table 2 Mean increase in intraocular pressure observed with topical corticosteroids in steroid responders (n = 10)
Preparation Final IOP Average IOP increase
(mean mmHg – SE) (mean mmHg – SE)
Dexamethasone 0.1% 45.1 ± 2.7 22.0 ± 2.9
Prednisolone 1.0% 32.3 ± 2.1 10.0 ± 1.7
Dexamethasone 0.005% 31.3 ± 2.4 8.2 ± 1.7
Fluorometholone 0.1% 29.2 ± 2.2 6.1 ± 1.4
Hydrocortisone 0.5% 26.3 ± 1.5 3.2 ± 1.0
Tetrahydrotriamcinolone 0.25% 24.9 ± 1.8 1.8 ± 1.3
Medrysone 1.0% 24.1 ± 1.8 1.0 ± 1.3
Adapted from [73]
IOP intraocular pressure, SE standard error
66 Ophthalmol Ther (2013) 2:55–72
123
were dosed sequentially with each of the
treatments, with a 1-month between-treatment
washout period. Dosing consisted of one drop
instilled four-times daily for 6 weeks or until there
was an IOP elevation of C10 mmHg. The mean
(SE) duration necessary to effect an elevation of
10 mmHg as compared to baseline was 29.5 (3.9)
days in the fluorometholone group when
compared with 22.7 (3.5) days in the
dexamethasone group (P = 0.015). As indicated
previously, the authors subsequently proposed
that an increase in IOP of C10 mmHg over
baseline should be considered clinically
significant.
Bartlett et al. [72] challenged 13 healthy
volunteers who were first-degree offspring of
individuals with primary open-angle glaucoma
with topically applied prednisolone phosphate
1%. Subjects were randomized to receive topical
prednisolone phosphate 1.0% in the left eye
and placebo in the right eye, or vice versa, for
up to 6 weeks. IOP was measured at day 0
(baseline) and at days 7, 14, 21, 28, 35, and 42.
After taking into account, the diurnal variation
in IOP (by subtracting the IOP in the control eye
from that in the treated eye), the authors
determined that seven patients (54%) had
maximum IOP elevations of 5–9 mmHg, and
two patients (15%) had IOP elevations of
C10 mmHg. The difference in the mean IOP
between the treated and control eyes was
significant (P\0.001).
The IOP-raising potential of newer
corticosteroids in known steroid responders
has also been documented. Leibowitz et al.
[50] compared the IOP-elevating potential of
rimexolone 1.0% and fluorometholone alcohol
0.1% in known steroid responders. In this two-
way crossover study, responders were defined as
those individuals who had exhibited an increase
in IOP of C10 mmHg when challenged for
up to 6 weeks with dexamethasone sodium
phosphate or prednisolone acetate. After a
1-month washout, responders were
administered either study drug (rimexolone or
fluorometholone) for a period of 6 weeks or
until an increase in IOP of C10 mmHg was
observed, whichever occurred first. This was
followed by another 1-month washout period
and administration of the alternate study
drug under the same conditions. In the 13
responders initially identified through
challenge with dexamethasone, the mean IOP
elevations were 11.8, 7.5, and 8.4 mmHg,
for dexamethasone, rimexolone, and
fluorometholone, respectively, while in the 20
responders initially identified through
challenge with prednisolone acetate, the mean
IOP elevations were 12.1, 6.2, and 3.5 mmHg
for prednisolone acetate, rimexolone, and
fluorometholone, respectively. There was no
difference between rimexolone and
fluorometholone in mean IOP elevation, the
number of patients demonstrating an IOP
increase of C10 mmHg (30% vs. 21%,
respectively) or mean time to response (5.2 vs.
5.4 weeks, respectively). Treatment with
rimexolone or fluorometholone resulted in a
significantly lower mean IOP elevation as
compared to treatment with dexamethasone
or prednisolone, and the mean time to
IOP elevation was significantly longer than in
treatment with dexamethasone or prednisolone
(2.5–3 weeks) (P B 0.02 for all).
Bartlett et al. [16] compared the effects of
loteprednol etabonate 0.5% and prednisolone
acetate 1.0% on IOP in 19 steroid responders
defined as individuals who had shown an
increase in IOP of C6 mmHg in B6 weeks
when treated with topical dexamethasone
0.1% or prednisolone acetate 1%. Patients
instilled one drop of loteprednol etabonate or
prednisolone acetate four-times daily for
6 weeks. After a 14-day washout period,
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patients entered the second 6-week phase of the
crossover and instilled the alternative study
medication. The mean increase in IOP over
the 42-day period was 4.1 and 9 mmHg for the
loteprednol etabonate group and prednisolone
acetate groups, respectively. By day 14, patients
in the prednisolone acetate group showed a
mean increase in IOP of 5.9 mmHg as compared
to baseline (P\0.05). The increase in IOP in
patients in the loteprednol etabonate group was
not significantly different from baseline.
Finally, Holland et al. [7] reported the
attenuation of ocular hypertension in steroid
responders after corneal transplantation. In this
retrospective review, 30 post-penetrating
keratoplasty and post-keratolimbal allograft
patients with IOP increases to C21 mmHg,
while being treated with prednisolone acetate
1.0% were switched to loteprednol etabonate
0.5%. Results showed a mean (SE) reduction of
IOP from 31.1 (1.13) mmHg for prednisolone
acetate as compared to 18.2 (1.37) mmHg for
loteprednol etabonate (P = 0.0001). The authors
concluded that loteprednol etabonate could be
a good alternative to prednisolone acetate in
the prophylaxis of allograft rejection in corneal
transplants.
Taken together, these studies in steroid
responders confirm a greater effect on IOP, both
mean IOP and/or IOP increases of C10 mmHg,
with prednisolone acetate and dexamethasone as
compared to fluorometholone and rimexolone,
and with prednisolone acetate as compared to
loteprednol etabonate.
CONCLUSION
The likelihood of a clinically significant increase
in IOP (C10 mmHg) is an important
consideration when deciding on which topical
corticosteroid is best suited to a patient.
Randomized, controlled studies to date, and
clinical studies in known steroid responders,
indicate that there are significant differences
among the common topical ophthalmic
corticosteroids used in the treatment of post-
operative inflammation: they are not the same
in terms of effects on IOP. The available data
indicate that dexamethasone and prednisolone
acetate, and the newer corticosteroid
difluprednate are more likely to result in
clinically significant increases in IOP as
compared to fluorometholone, rimexolone,
and loteprednol etabonate. However, further
head-to-head studies comparing the proportion
of patients exhibiting clinically significant
increases in IOP (C10 mmHg) with different
corticosteroids, particularly the newer topical
ocular corticosteroids, are warranted. In
addition, studies assessing the precise
mechanism of decreased IOP effect with
certain corticosteroids, whether because of
rapid metabolism or poor ocular penetration,
etc., are also needed. Of the corticosteroid
choices currently available, ample published
data were found in support of a minimal effect
on IOP with loteprednol etabonate, even when
studied in known steroid responders.
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